Roche enters licensing deal with Nurix Therapeutics for blood cancer drug worth up to $2.3-3 billion

Roche is licensing Nurix Therapeutics' blood cancer drug, bexobrutideg, in a deal worth up to $3 billion, including a $700 million upfront payment. The drug is a novel BTK protein degrader designed to overcome treatment resistance. The partnership, which will advance the drug into Phase 3 trials, was praised by analysts and caused Nurix's stock to surge 21%. The deal expands Roche's pipeline in the competitive protein degrader space.

Roche-Nurix licensing deal terms

• ▪Roche will cover 60% of development costs, and the companies will split U.S. profits and losses equally.
• ▪The deal includes a $700 million upfront payment to Nurix and up to $2.3 billion in development, regulatory, and sales milestones.
• ▪Roche entered a licensing deal with Nurix Therapeutics for the blood cancer drug bexobrutideg, worth up to $3 billion.

Bexobrutideg BTK degrader mechanism

• ▪The drug uses a cell's own machinery to degrade the BTK protein, potentially overcoming treatment resistance seen with traditional BTK inhibitors.
• ▪Bexobrutideg is an orally available protein degrader that destroys the BTK protein, a key signaling molecule in B cells.

B cell malignancy development plans

• ▪The partnership's clinical development plan covers B-cell malignancies and will also span immunology and neurology.
• ▪The partners plan to advance bexobrutideg into a Phase 3 trial for chronic lymphocytic leukemia in the summer of 2026.

Protein degrader partnership strategy

• ▪Other major pharmaceutical firms like Novartis, Biogen, and Takeda are also investing heavily in molecular glue degraders.
• ▪Roche also has an ongoing protein degrader partnership with C4 Therapeutics, which it expanded in April 2026 for up to $1 billion.
• ▪The deal is part of Roche's strategy to add protein degraders to its oncology drug pipeline.

Analyst assessment of deal

• ▪Analysts at Truist Securities described the partnership as "sensible and validating" for bexobrutideg's clinical profile and potential safety.
• ▪Truist Securities stated the deal helps Nurix address the "capital intensity and execution risk" of advancing its BTK degrader program.
• ▪Following the announcement on June 8, 2026, Nurix Therapeutics' stock surged 21% to $17.74 in pre-market trading.

2 sources